https://mindmedicinelaw.com/briefing/arizona-s-psilocybin-trial-progress-and-implications-20260605-10354The Psychedelic Journalen2026-06-05T22:04:21.914941+00:00Arizona's Psilocybin Trial: Progress and Implicationspsilocybin trial, Arizona, psychedelic research, mental health, clinical trials, regulatory policy, serotonin receptors, Schedule I substance, treatment-resistant conditionshttps://mindmedicinelaw.com/briefing/epa-s-proposed-snurs-under-tsca-impacts-on-psychedelic-research-20260605-10064The Psychedelic Journalen2026-06-05T22:04:14.238920+00:00EPA's Proposed SNURs Under TSCA: Impacts on Psychedelic ResearchEPA, SNURs, TSCA, psychedelic research, chemical substances, regulatory compliance, manufacturing, import, notification, policyhttps://mindmedicinelaw.com/briefing/post-trial-psilocybin-access-legal-reflections-in-the-uk-20260605-10197The Psychedelic Journalen2026-06-05T15:05:11.837310+00:00Post-Trial Psilocybin Access: Legal Reflections in the UKpsilocybin, post-trial access, UK legal case, psychedelic research, clinical trials, Schedule 1 drugs, patient access, regulatory frameworks, mental health treatment, legal complexitieshttps://mindmedicinelaw.com/briefing/eeg-study-explores-awe-in-affective-disorders-20260604-10118The Psychedelic Journalen2026-06-05T22:04:40.390349+00:00EEG Study Explores Awe in Affective Disordersaffective disorders, awe experience, EEG study, virtual reality, emotional processing, neural activity, theta oscillations, therapeutic interventions, mental health treatment, neurobiological researchhttps://mindmedicinelaw.com/briefing/ketamine-induced-neuronal-death-adult-rats-study-insights-20260604-10129The Psychedelic Journalen2026-06-05T22:04:33.097835+00:00Ketamine-Induced Neuronal Death: Adult Rats Study Insightsketamine neurotoxicity, adult female rats, neuronal necrosis, norketamine metabolite, depression treatment, safety profile, clinical research, age-specific risks, sex-specific vulnerability, psychedelic researchhttps://mindmedicinelaw.com/briefing/ai-chatbots-and-substance-induced-psychosis-clinical-concerns-20260604-10083The Psychedelic Journalen2026-06-05T15:05:29.597502+00:00AI Chatbots and Substance-Induced Psychosis: Clinical ConcernsAI chatbots, substance-induced psychosis, mental health, clinical implications, ethical concerns, harm minimizationhttps://mindmedicinelaw.com/briefing/mdma-booster-dose-study-implications-for-clinical-trials-20260604-10103The Psychedelic Journalen2026-06-05T15:05:22.021857+00:00MDMA Booster Dose Study: Implications for Clinical TrialsMDMA booster dose, psychedelic therapy, PTSD treatment, clinical trials, subjective effects, adverse effects, dosing protocols, psychiatric disorders, MDMA-assisted therapy, neuroscience researchhttps://mindmedicinelaw.com/briefing/connecticut-expands-psychedelics-program-ahead-of-fda-approval-20260604-10195The Psychedelic Journalen2026-06-05T15:05:00.074307+00:00Connecticut Expands Psychedelics Program Ahead of FDA Approvalconnecticut psychedelics program, FDA approval, psychedelic therapy, state-level policy, clinical trials, psychedelics legal landscapehttps://mindmedicinelaw.com/briefing/ketamine-therapy-gains-traction-in-las-vegas-clinic-20260604-10037The Psychedelic Journalen2026-06-04T22:04:17.711278+00:00Ketamine Therapy Gains Traction in Las Vegas Clinicketamine therapy, mental health, psychedelic treatments, Las Vegas clinic, alternative therapies, clinical research, policy implications, treatment risks, healthcare integration, patient outcomeshttps://mindmedicinelaw.com/briefing/ketamine-oxytocin-nasal-spray-a-new-frontier-in-la-20260604-10036The Psychedelic Journalen2026-06-04T22:04:10.874021+00:00Ketamine-Oxytocin Nasal Spray: A New Frontier in LAketamine, oxytocin, nasal spray, treatment-resistant depression, PTSD, compounded formulations, mental health treatment, clinical trials, regulatory scrutiny, psychedelic therapieshttps://mindmedicinelaw.com/briefing/n100-and-fronto-limbic-metabolism-in-mdd-new-insights-20260603-10135The Psychedelic Journalen2026-06-05T22:04:47.386129+00:00N100 and Fronto-Limbic Metabolism in MDD: New InsightsN100 potential, major depressive disorder, GABAergic systems, cerebral glucose metabolism, transcranial magnetic stimulation, compensatory mechanism, fronto-limbic metabolism, Hamilton Depression Rating Scale, targeted therapies, neurophysiological mechanismhttps://mindmedicinelaw.com/briefing/hnk-s-antidepressant-mechanism-opioid-receptor-heterodimerization-20260603-10133The Psychedelic Journalen2026-06-05T15:05:50.180478+00:00HNK's Antidepressant Mechanism: Opioid Receptor HeterodimerizationHNK, opioid receptor heterodimerization, antidepressant mechanism, ketamine metabolite, astrocytic receptors, rapid-acting antidepressants, mental health treatment, neuroscience, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/shared-molecular-pathways-in-mood-disorders-new-insights-20260603-10134The Psychedelic Journalen2026-06-05T15:05:39.767004+00:00Shared Molecular Pathways in Mood Disorders: New Insightsmood disorders, human habenula, transcriptomic profiling, major depressive disorder, bipolar disorder, sex-informed research, neurobiology, therapeutic strategies, gene expression, psychiatric researchhttps://mindmedicinelaw.com/briefing/integrated-treatment-model-for-opioid-use-schizophrenia-20260603-9788The Psychedelic Journalen2026-06-04T15:05:20.414039+00:00Integrated Treatment Model for Opioid Use & Schizophreniaintegrated treatment model, opioid use disorder, schizophrenia spectrum disorders, dual-diagnosis, clinical outcomes, medication adherence, emergency department visits, healthcare policy, patient engagement, mental healthhttps://mindmedicinelaw.com/briefing/iboga-microdosing-in-tbi-recovery-emerging-evidence-20260603-9801The Psychedelic Journalen2026-06-04T15:04:50.100218+00:00Iboga Microdosing in TBI Recovery: Emerging Evidenceiboga microdosing, traumatic brain injury, hypoxic brain injury, psychedelic therapy, clinical trials, neurological recovery, AEDP, ibogaine, psychedelic research, neurorehabilitationhttps://mindmedicinelaw.com/briefing/placebo-effects-in-psychedelic-research-implications-for-trials-20260602-9769The Psychedelic Journalen2026-06-04T15:05:07.938325+00:00Placebo Effects in Psychedelic Research: Implications for Trialsplacebo effects, psychedelic research, clinical trials, contextual influence, altered states of consciousness, ego dissolution, nocebo effects, set and setting, trait responsiveness, therapeutic applicationshttps://mindmedicinelaw.com/briefing/european-consensus-on-trlld-framework-for-future-research-20260602-9813The Psychedelic Journalen2026-06-04T15:04:58.979987+00:00European Consensus on TRLLD: Framework for Future Researchtreatment-resistant late-life depression, TRLLD, European task force, Delphi process, depression in elderly, clinical guidelines, operational staging model, decision-making algorithm, psychiatric research, mental health policyhttps://mindmedicinelaw.com/briefing/esketamine-and-psychotherapy-promising-combo-for-trd-20260602-9812The Psychedelic Journalen2026-06-04T15:04:27.391611+00:00Esketamine and Psychotherapy: Promising Combo for TRDesketamine, psychotherapy, treatment-resistant depression, ketamine-assisted psychotherapy, clinical trial, mental health treatment, neuroplasticity, pharmacological effects, emotional processing, integrated treatmenthttps://mindmedicinelaw.com/briefing/ketamine-s-potential-in-treating-chemobrain-a-preclinical-study-20260601-9814The Psychedelic Journalen2026-06-04T22:04:24.131366+00:00Ketamine's Potential in Treating Chemobrain: A Preclinical Studyketamine, chemobrain, depression, neuroinflammation, cancer treatment, preclinical study, signaling pathways, BDNF/TrkB, GLT-1, SERThttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-reducing-postoperative-anxiety-in-adolescents-20260601-9818The Psychedelic Journalen2026-06-04T15:04:39.998171+00:00Esketamine's Role in Reducing Postoperative Anxiety in Adolescentsesketamine, postoperative anxiety, adolescents, randomized controlled trial, perioperative care, psychological distresshttps://mindmedicinelaw.com/briefing/ketamine-s-dual-effects-neurotoxicity-and-neuroprotection-20260527-10175The Psychedelic Journalen2026-06-05T22:04:04.870135+00:00Ketamine's Dual Effects: Neurotoxicity and Neuroprotectionketamine, esketamine, neurotoxicity, neuroprotection, clinical guidelines, brain health, therapeutic use, systematic review, neuroscience, public health